Cargando…

Trastuzumab Biosimilars in the Therapy of Breast Cancer – “Real World” Experiences from four Bavarian University Breast Centres

Introduction With the introduction of the first trastuzumab biosimilar in the summer of 2018, biosimilar antibodies for breast cancer have found their way into the area of gynaecological oncology. The switch of anti-human epidermal growth factor receptor 2 (HER2) therapy from the reference drug Herc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hester, Anna, Gaß, Paul, Fasching, Peter A., Krämer, Anne Katrin, Ettl, Johannes, Diessner, Joachim, Wöckel, Achim, Egger, Tobias, Stock, Katja, Redlin, Jutta, Andraschko, Monika, Harbeck, Nadia, Würstlein, Rachel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Georg Thieme Verlag KG 2020
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7467805/ https://www.ncbi.nlm.nih.gov/pubmed/32905322 http://dx.doi.org/10.1055/a-1226-6666

Ejemplares similares

Concepts and Challenges of Biosimilars in Breast Cancer: The Emergence of Trastuzumab Biosimilars
por: Uifălean, Alina, et al.
Publicado: (2018)

Bavarian Universities
Publicado: (1837)

Systematic Review on the Use of Biosimilars of Trastuzumab in HER2+ Breast Cancer
por: Triantafyllidi, Eleni, et al.
Publicado: (2022)

Neoadjuvant PF-05280014 (a potential trastuzumab biosimilar) versus trastuzumab for operable HER2+ breast cancer
por: Lammers, Philip E., et al.
Publicado: (2018)

Targeting of preexisting and induced breast cancer stem cells with trastuzumab and trastuzumab emtansine (T-DM1)
por: Diessner, J, et al.
Publicado: (2014)

Cost effectiveness of using trastuzumab biosimilars compared to trastuzumab original drugs to treat breast cancer in a hospital setting
por: Barat, Eric C., et al.
Publicado: (2023)

Dermatomyositis following Biosimilar Trastuzumab in a Breast Cancer Patient: A Case Report
por: Moghimi, Minoosh, et al.
Publicado: (2021)

The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars
por: Barbier, Liese, et al.
Publicado: (2019)

Update Breast Cancer 2023 Part 2 – Advanced-Stage Breast Cancer
por: Lux, Michael P., et al.
Publicado: (2023)

Update Breast Cancer 2023 Part 1 – Early Stage Breast Cancer
por: Hartkopf, Andreas D., et al.
Publicado: (2023)

Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice
por: Waller, Cornelius F., et al.
Publicado: (2021)

Population pharmacokinetics of PF-05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin(®)) in patients with HER2-positive metastatic breast cancer
por: Chen, Xiaoying, et al.
Publicado: (2019)

A Review of Trastuzumab Biosimilars in Early Breast Cancer and Real World Outcomes of Neoadjuvant MYL-1401O versus Reference Trastuzumab
por: Yang, Charlie, et al.
Publicado: (2022)

Comparison of Biosimilar Trastuzumab ABP 980 with Reference Trastuzumab in Neoadjuvant Therapy for HER2-positive Breast Cancer – an Analysis of a Large University Breast Cancer Centre
por: Matovina, Sabine, et al.
Publicado: (2022)

Update Breast Cancer 2023 Part 3 – Expert Opinions of Early Stage Breast Cancer Therapies
por: Kolberg, Hans-Christian, et al.
Publicado: (2023)

Physicochemical and Biological Characterization of a Biosimilar Trastuzumab
por: López-Morales, Carlos A., et al.
Publicado: (2015)

Correction to: Population pharmacokinetics of PF‑05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin(®)) in patients with HER2‑positive metastatic breast cancer
por: Chen, Xiaoying, et al.
Publicado: (2019)

Update Breast Cancer 2022 Part 2 – Advanced Stage Breast Cancer
por: Müller, Volkmar, et al.
Publicado: (2022)

Advanced Breast Cancer: AGO Recommendations 2022 – Focus on ABC6 Consensus
por: Untch, Michael, et al.
Publicado: (2022)

Safety survey on infusion reaction and cardiac dysfunction when switching from reference trastuzumab (HERCEPTIN(®)) to biosimilar trastuzumab (Trastuzumab‑NK) in the treatment of HER2‑positive breast cancer
por: Abe, Tomoya, et al.
Publicado: (2023)

Simulating Costs of Intravenous Biosimilar Trastuzumab vs. Subcutaneous Reference Trastuzumab in Adjuvant HER2-Positive Breast Cancer: A Belgian Case Study
por: Simoens, Steven, et al.
Publicado: (2021)

Update Breast Cancer 2022 Part 1 – Early Stage Breast Cancer
por: Welslau, Manfred, et al.
Publicado: (2022)

A phase I dose-escalation study of a biosimilar trastuzumab in Chinese metastasis breast cancer patients
por: Zhou, Xinna, et al.
Publicado: (2015)

Evaluation of different imaging modalities for axillary lymph node staging in breast cancer patients to provide a personalized and optimized therapy algorithm
por: Diessner, Joachim, et al.
Publicado: (2022)

Update Breast Cancer 2020 Part 4 – Advanced Breast Cancer
por: Tesch, Hans, et al.
Publicado: (2020)

Functional and Nonclinical Similarity of ABP 980, a Biosimilar of Trastuzumab
por: Jassem, Shea, et al.
Publicado: (2019)

Evaluation of clinical parameters influencing the development of bone metastasis in breast cancer
por: Diessner, Joachim, et al.
Publicado: (2016)

Optimized process quality in certified breast centers through adherence to stringent diagnostic and therapeutic algorithms effects of structural as well as socio-demographic factors on start of therapy
por: Herbert, Saskia-Laureen, et al.
Publicado: (2022)

Update Breast Cancer 2020 Part 3 – Early Breast Cancer
por: Huober, Jens, et al.
Publicado: (2020)

Prognostic effect of HER2 evolution from primary breast cancer to breast cancer metastases
por: Löb, Sanja, et al.
Publicado: (2022)

The Bavarian working group on antibiotic resistant pathogens (LARE)
por: Kandler, U, et al.
Publicado: (2015)

The effects of the COVID-19 pandemic on psychological stress in breast cancer patients
por: Bartmann, Catharina, et al.
Publicado: (2021)

4th International Consensus Conference on Advanced Breast Cancer (ABC4), Lisbon, November 4, 2017 : ABC4 Consensus: Assessment by a Panel of German Experts
por: Untch, Michael, et al.
Publicado: (2018)

Do Patients with Luminal A Breast Cancer Profit from Adjuvant Systemic Therapy? A Retrospective Multicenter Study
por: Diessner, Joachim, et al.
Publicado: (2016)

Update Breast Cancer 2021 Part 5 – Advanced Breast Cancer
por: Lüftner, Diana, et al.
Publicado: (2022)

The impact of breast cancer biological subtyping on tumor size assessment by ultrasound and mammography - a retrospective multicenter cohort study of 6543 primary breast cancer patients
por: Stein, Roland Gregor, et al.
Publicado: (2016)

Update Breast Cancer 2019 Part 2 – Implementation of Novel Diagnostics and Therapeutics in Advanced Breast Cancer Patients in Clinical Practice
por: Janni, Wolfgang, et al.
Publicado: (2019)

Update Breast Cancer 2020 Part 1 – Early Breast Cancer: Consolidation of Knowledge About Known Therapies
por: Schneeweiss, Andreas, et al.
Publicado: (2020)

Correction: Update Breast Cancer 2021 Part 5 – Advanced Breast Cancer
por: Lüftner, Diana, et al.
Publicado: (2022)

Comparative Nonclinical Assessments of the Proposed Biosimilar PF-05280014 and Trastuzumab (Herceptin(®))
por: Hurst, Susan, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_9co41la0s5q0j4gj5ng6qakdue